<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="27881">Resveratrol</z:chebi> is a polyphenolic compound that exhibits anti-proliferative and anti-inflammatory activities </plain></SENT>
<SENT sid="1" pm="."><plain>BCL6, a transcriptional repressor frequently translocated in <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, including diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and transformed follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), regulates germinal center B-cell differentiation </plain></SENT>
<SENT sid="2" pm="."><plain>We report herein that <z:chebi fb="0" ids="27881">resveratrol</z:chebi> treatment of human LY8 follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells leads to an accumulation of LY8 cell in G0/G1 phase and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="27881">Resveratrol</z:chebi> decreased the expression of BCL6 protein, concomitant with the increased expression of several BCL6 regulated gene products, including p27, p53 and CD69 </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, <z:chebi fb="0" ids="27881">resveratrol</z:chebi> reduces Myc expression in LY8 cells </plain></SENT>
<SENT sid="5" pm="."><plain>These results demonstrate for the first time that <z:chebi fb="0" ids="27881">resveratrol</z:chebi> inhibits a BCL6-linked pathway and suggest that loss of BCL6 expression may represent a key event underlying the anti-proliferative activities of <z:chebi fb="0" ids="27881">resveratrol</z:chebi> on LY8 cells </plain></SENT>
<SENT sid="6" pm="."><plain>The use of <z:chebi fb="0" ids="27881">resveratrol</z:chebi> to treat aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with BCL6 and/or MYC translocations may prove useful as an effective therapy </plain></SENT>
</text></document>